Abstract Number: 0641 • ACR Convergence 2020
Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?
Background/Purpose: There are very few studies reporting COVID-19 in patients with rheumatic diseases, without clear evidence supporting more frequent or severe disease in these patients.…Abstract Number: 0993 • ACR Convergence 2020
N-linked Glycosylation of the Immunoglobulin Variable Domain Affects Antigen Binding and Autoreactive B Cell Activation
Background/Purpose: Anti-citrullinated protein antibodies, the hallmarking autoantibodies in Rheumatoid Arthritis (RA), are characterized by N-linked glycans in the variable domain (V-domain). The occurrence of these…Abstract Number: 1133 • ACR Convergence 2020
Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies
Background/Purpose: The diagnosis and treatment of inflammatory arthritis has been transformed largely by the development of drugs that target specific molecules of the immune system.…Abstract Number: 1405 • ACR Convergence 2020
Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry
Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and…Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…Abstract Number: 147 • 2020 Pediatric Rheumatology Symposium
Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
Background/Purpose: Recent epidemiologic studies have reported increased rates of immune-mediated comorbidities among first-degree relatives of patients with OCD and tic disorders.(Mataix-Cols et al., Mol Psychiatry…Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…Abstract Number: 62 • 2019 ACR/ARP Annual Meeting
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted. Mesenchymal…Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…Abstract Number: 102 • 2019 ACR/ARP Annual Meeting
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)
Background/Purpose: CD4 T helper 1 (Th1) and Th17 cells producing IFN-γ and IL-17 are aberrantly increased and contribute to inflammatory responses in autoimmune diseases including…Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…Abstract Number: 103 • 2019 ACR/ARP Annual Meeting
Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
Background/Purpose: Regulatory T cells (Tregs) are pivotal in enforcing immune tolerance to prevent and protect from autoimmunity. Defects in Tregs lead to unchecked immune cell…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 80
- Next Page »